Multidrug-resistant Human Lung Cancer Cells Research Articles

MiR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2

MicroRNAs (miRNAs) are short non-coding RNA molecules, which posttranscriptionally regulate genes expression and play crucial roles in diverse biological processes, such as development, differentiation, apoptosis, and proliferation. Here, we investigated the possible role of miRNAs in the development of multidrug resistance (MDR) in human gastric and lung cancer cell lines. We found that miR-497 was downregulated in both multidrug-resistant human gastric cancer cell line SGC7901/vincristine (VCR) and multidrug-resistant human lung cancer cell line A549/cisplatin (CDDP) and the downregulation of miR-497 was concurrent with the upregulation of BCL2 protein, compared with the parental SGC7901 and A549 cell lines, respectively. In vitro drug sensitivity assay demonstrated that overexpression of miR-497 sensitized SGC7901/VCR and A549/CDDP cells to anticancer drugs, respectively. The luciferase activity of BCL2 3'-untranslated region-based reporter constructed in SGC7901/VCR and A549/CDDP cells suggested that BCL2 was the direct target gene of miR-497. Enforced miR-497 expression reduced BCL2 protein level and sensitized SGC7901/VCR and A549/CDDP cells to VCR-induced and CDDP-induced apoptosis, respectively. Taken together, our findings first suggested that has-miR-497 could play a role in both gastric and lung cancer cell lines at least in part by modulation of apoptosis via targeting BCL2.

MiR‐181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines

MicroRNAs (miRNAs) are short noncoding RNA molecules, which posttranscriptionally regulate genes expression and play crucial roles in diverse biological processes, such as development, differentiation, apoptosis and proliferation. Here, we investigated the possible role of miRNAs in the development of multidrug resistance (MDR) in human gastric and lung cancer cell lines. We found that miR-181b was downregulated in both multidrug-resistant human gastric cancer cell line SGC7901/vincristine (VCR) and multidrug-resistant human lung cancer cell line A549/cisplatin (CDDP), and the downregulation of miR-181b in SGC7901/VCR and A549/CDDP cells was concurrent with the upregulation of BCL2 protein, compared with the parental SGC7901 and A549 cell lines, respectively. In vitro drug sensitivity assay demonstrated that overexpression of miR-181b sensitized SGC7901/VCR and A549/CDDP cells to anticancer drugs, respectively. The luciferase activity of a BCL2 3'-untranslated region-based reporter construct in SGC7901/VCR and A549/CDDP cells suggests that a new target site in the 3'UTR of BCL2 of the mature miR-181s (miR-181a, miR-181b, miR-181c and miR-181d) was found. Enforced miR-181b expression reduced BCL2 protein level and sensitized SGC7901/VCR and A549/CDDP cells to VCR-induced and CDDP-induced apoptosis, respectively. Taken together, our findings suggest that miR-181b could play a role in the development of MDR in both gastric and lung cancer cell lines, at least in part, by modulation of apoptosis via targeting BCL2.

Enhancement of the efficacy of chemotherapy for lung cancer by simultaneous suppression of multidrug resistance and antiapoptotic cellular defense: novel multicomponent delivery system.

The efficacy of chemotherapy of lung cancer is limited by the development of resistance in cancer cells during treatment. In most lung cancers, this resistance is associated with the overexpression of (a) multidrug resistance-associated protein (MRP) responsible for drug efflux from the cancer cells (pump resistance) and (b) BCL2 protein that activates antiapoptotic cellular defense (nonpump resistance). A novel liposomal proapoptotic anticancer drug delivery system was developed to enhance anticancer efficacy of the well-established drug doxorubicin (DOX). This multicomponent drug delivery system was tested on multidrug-sensitive and -resistant human small-cell lung cancer cells. The drug delivery system includes four components: (a) liposome as a carrier, (b) DOX as an inductor of apoptosis, (c) antisense oligonucleotides (ASOs) targeted to MRP1 mRNA as a suppressor of pump resistance, and (d) ASOs targeted to BCL2 mRNA as a suppressor of nonpump resistance. Intracellular internalization of ASOs and DOX; the influence of the proposed system on the expression of genes and proteins involved in the multidrug resistance, cytotoxicity, and apoptosis induction and antiapoptotic defense; and the activity of caspases were studied. It was found that the proposed liposomal delivery system successfully delivered ASOs and DOX to cell nuclei, inhibited MRP1 and BCL2 protein synthesis, and substantially increased the anticancer action of DOX by stimulating the caspase-dependent pathway of apoptosis in multidrug-resistant human lung cancer cells.

45] Transport function and substrate specificity of multidrug resistance protein

Publisher Summary This chapter describes the multidrug resistance protein (MRP1) that has been cloned and sequenced from multidrug-resistant human lung cancer cells and identified as an integral membrane glycoprotein belonging to the superfamily of adenosine triphosphate-binding cassette (ABC) transporters. Primary active unidirectional adenosine triphosphate (ATP)-dependent transport of amphiphilic anions—in particular, of conjugates of lipophilic substances with glutathione, glucuronate, or sulfate, are the recognized functions of MRP1. An isoform of MRP1 with a related sequence and a similar function has been cloned from human and rat and localized predominantly to the hepatocyte canalicular membrane. This isoform is termed “MRP2” or “canalicular MRP” (cMRP) or “canalicular multispecific organic anion transporter” (cMOAT). Canalicular (apical) MRP is deficient in human Dubin–Johnson syndrome and in two mutant rat strains lacking the ATP-dependent transport of anionic conjugates across the hepatocyte canalicular membrane.

Combined therapy of p53-wt and drug in an orthotopic multidrug-resistant human lung cancer model

Balb/c nu/nu mice were inoculated intratracheally with multidrug-resistant human lung cancer cells GLK containing p53 mutation at codon 245 and treated with intratracheal instillation of p53-wt retroviral vector (pDOR53W) to increase cell chemosensitivity, and then with intraperitoneal injection of doxorubicin. 30 d after tumor cell inoculation, 75% of the control mice showed macroscopic tumors in the lung. Sole pDOR53W suppressed GLK tumor formation in 68% of mice; sole doxorubicin 33.3%, but the combination of pDOR53W and doxorubicin 88.9 %. The exogenous p53 sequence was detected and confirmed in the tumor that grew after treatment with pDOR53W retroviral vector by PCR and Southern blot hybridization with p53 cDNA. These results suggested that direct administration of a retroviral vector expressing p53-wt combined with treatment of anticancer agent was an effective therapeutic method for multidrug-resistant human lung cancer.

Clinical Significance of Multi-Drug Resistance Associated Protein and P-Glycoprotein in Patients with Bladder Cancer

The clinical significance of multi-drug resistant proteins, such as multi-drug resistance associated protein and P-glycoprotein, in terms of prognostic value was determined in patients with bladder cancer. The expression of multi-drug resistance associated protein and P-glycoprotein was investigated immunohistochemically before and after chemotherapy. The relationship between expression of these multi-drug resistant proteins and clinical outcome assessed by tumor recurrence rate, cystectomy rate and 5-year survival rate was also investigated in 33 patients with bladder cancer. Before chemotherapy multi-drug resistance associated protein expression was observed in 1 of 28 patients (4%) while P-glycoprotein expression was observed in 22 of 33 (67%). Multi-drug resistance associated protein induction by chemotherapy was observed in 6 of 28 patients (21%), whereas P-glycoprotein induction was noted in 4 (14%). Multi-drug resistance associated protein in this disease is induced more frequently by high dose (more than 300 mg.) than low dose (less than 300 mg.) anthracyclines (p < 0.01). Immunohistochemical analysis also revealed co-expression of multi-drug resistance associated protein and P-glycoprotein in 5 of 28 patients (18%) after chemotherapy. However, there was no significant correlation between positive P-glycoprotein expression before chemotherapy and clinical outcome. Multi-drug resistance associated protein as well as P-glycoprotein mediated multi-drug resistance may be induced after chemotherapy for bladder tumors. However, the presence of P-glycoprotein before chemotherapy does not predict clinical outcome in patients with bladder cancer.

Reversal of drug resistance of multidrug-resistant human lung cancer cells by an MDR1 ribozyme

MALIGNANT tumor is very harmful to human health, and the mortality is very high. About 50% of the patients with malignancy can be operated on, and the other 50% patients have to be treated with chemotherapy. Because tumors are mostly chemoresistant, chemotherapy for these patients often has no effect. The overexpression of MDR1 gene is very common in hu man malignant tumors, about 50% in previously untreated patients and more than 50% in previously treated patients for whom the tumor is resistant to the previous sensitive anticancer....

Reversal of drug resistance in multidrug-resistant human lung cancer cells by MRP antisense RNA mediated by retrovirus

DRUG resistance of tumor is a very common phenomenon in clinical tumor treatment. Most patients with lung cancers, one of the most common malignant tumors in China, have no response to chemotherapy, so it is very important to study the resistant biology of lung cancer for treatment. The rate of drug sensitivity in non-small cell lung cancer (NSCLC) is lower than in small cell lung cancer (SCLC). The drug resistance, besides the effects of MDRl genet'] and GST-X'~], is also closely correlated with the effect of another novel gene MRP (multidrug resistance-related gene)[31. In the previous study on a doxorubicin-selected human NSCLC cell line, GAOK, we found that MDRl gene overexpressed and MDRl antisense RNA mediated by retrovirus could not completely reverse the phenotype of multidrug resistance['], and MRP gene and its coding product Mrp (multidrug resistance protein) also overexpressed. In the present study, in order to understand the effect of MRP in GAOK cells and possibility of reversing the multidrug resistance, we introduced MRP antisense RNA mediated by retrovirus into GAOK cells, and observed its expression and the change of multidrug resistance.

The P-glycoprotein-related gene family in Leishmania

P-glycoprotein gene amplification has been described in several drug-resistant parasitic protozoa. The first P-glycoprotein related gene described in Leishmania was ltpgpA, a gene frequently amplified in arsenite resistant Leishmania. Hybridization experiments indicated that ltpgpA was part of a gene family. In addition to ltpgpA, four novel genes were cloned that are present in two loci: ltpgpB and ltpgpC tandemly linked to ltpgpA on a 800-kb chromosome; and ltpgpD and ltpgpE closely linked on a chromosome ranging from 950 kb to 1400 kb, depending on the Leishmania species. Another P-glycoprotein gene, homologous to the more recently described ldmdrl, was linked to ltpgpD and ltpgpE. Nucleotide sequencing of ltpgpB and ltpgpE revealed that the Leishmania P-glycoprotein-related genes have diverged considerably from the main branch of P-glycoproteins and are more homologous to the recently described multidrug resistance-associated protein found in multidrug-resistant human lung cancer cell lines. Cross-resistance studies and gene transfection experiments indicated that under the conditions tested only ltpgpA and ldmdrl are involved in resistance to arsenite and antimonials or hydrophobic drugs such as vinblastine respectively.